A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
Clinical trial NCT02468661 · TERMINATED
Trial details
- NCT number
- NCT02468661
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-09-23
- Primary completion
- 2017-11-15
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.